Potential to fit in beautifully with the current thinking

“There really is a universally agreed upon feeling that wet AMD therapy will include a multifactorial approach and more and more retinal specialists are looking for ways to manage their patients as the frequency of the intra-vitreal injections is becoming unmanageable. Choroidal Vessel Closure (CVC) with OPTTX has the potential to fit in beautifully with the current thinking and the post-market registry trial looking at CVC in combination with the anti-VEGFs has the potential to reduce the number of injections needed in the management of this disease.”